Literature DB >> 16533497

Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Roberto Ciccocioppo1, Daina Economidou, Roberto Rimondini, Wolfgang Sommer, Maurizio Massi, Markus Heilig.   

Abstract

BACKGROUND: Activation of the NOP receptor by its endogenous ligand nociceptin/orphanin FQ reduces ethanol intake in genetically selected alcohol preferring Marchigian Sardinian alcohol preferring (msP) rats. Here we evaluated whether buprenorphine, a partial agonist at micro-opioid and NOP receptors, would reduce ethanol consumption in msP rats via activation of NOP receptors.
METHODS: Marchigian Sardinian alcohol preferring rats trained to drink 10% alcohol 2 hours/day were injected with buprenorphine (.03, .3, 3.0, or 6.0 mg/kg intraperitoneally [IP]) 90 min before access to ethanol.
RESULTS: Similar to prototypical micro-agonists, the two lowest doses of buprenorphine significantly increased ethanol consumption (p < .01); in contrast, the two highest doses reduced it (p < .05). Pretreatment with naltrexone (.25 mg/kg IP) prevented the increase of ethanol intake induced by .03 mg/kg of buprenorphine (p < .001) but did not affect the inhibition of ethanol drinking induced by 3.0 mg/kg of buprenorphine. Conversely, pretreatment with the selective NOP receptor antagonist UFP-101 (10.0 or 20.0 microg/rat) abolished the suppression of ethanol drinking by 3.0 mg/kg of buprenorphine.
CONCLUSIONS: Buprenorphine has dualistic effects on ethanol drinking; low doses increase alcohol intake via stimulation of classic opioid receptors, whereas higher doses reduce it via activation of NOP receptors. We suggest that NOP agonistic properties of buprenorphine might be useful in the treatment of alcoholism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533497      PMCID: PMC3035814          DOI: 10.1016/j.biopsych.2006.01.006

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  88 in total

1.  Buprenorphine has potent kappa opioid receptor antagonist activity.

Authors:  J D Leander
Journal:  Neuropharmacology       Date:  1987-09       Impact factor: 5.250

2.  In vivo receptor binding of opioid drugs at the mu site.

Authors:  J S Rosenbaum; N H Holford; W Sadée
Journal:  J Pharmacol Exp Ther       Date:  1985-06       Impact factor: 4.030

3.  The clinical implications of primary diagnostic groups among alcoholics.

Authors:  M A Schuckit
Journal:  Arch Gen Psychiatry       Date:  1985-11

4.  Psychopathology in hospitalized alcoholics.

Authors:  M N Hesselbrock; R E Meyer; J J Keener
Journal:  Arch Gen Psychiatry       Date:  1985-11

5.  Alcohol use and abuse: heavy drinking among methadone clients.

Authors:  D E Hunt; D L Strug; D S Goldsmith; D S Lipton; K Robertson; L Truitt
Journal:  Am J Drug Alcohol Abuse       Date:  1986       Impact factor: 3.829

Review 6.  The treatment of alcoholic methadone patients: a review.

Authors:  W K Bickel; I Marion; J H Lowinson
Journal:  J Subst Abuse Treat       Date:  1987

7.  Postoperative pain relief with high-dose epidural buprenorphine: a double-blind study.

Authors:  R Y Gundersen; R Andersen; G Narverud
Journal:  Acta Anaesthesiol Scand       Date:  1986-11       Impact factor: 2.105

8.  Comparison of intramuscular buprenorphine and a buprenorphine/naloxone combination in the treatment of post-operative pain.

Authors:  B Vanacker; E Vandermeersch; J Tomassen
Journal:  Curr Med Res Opin       Date:  1986       Impact factor: 2.580

9.  Psychopathology as a predictor of treatment outcome in alcoholics.

Authors:  B J Rounsaville; Z S Dolinsky; T F Babor; R E Meyer
Journal:  Arch Gen Psychiatry       Date:  1987-06

10.  Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations.

Authors:  C L Hubbell; S A Czirr; G A Hunter; C M Beaman; N C LeCann; L D Reid
Journal:  Alcohol       Date:  1986 Jan-Feb       Impact factor: 2.405

View more
  45 in total

1.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

2.  Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection.

Authors:  Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin
Journal:  J Subst Abuse Treat       Date:  2016-06-06

Review 3.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

4.  Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Authors:  Marsida Kallupi; Qianwei Shen; Giordano de Guglielmo; Dennis Yasuda; V Blair Journigan; Nurulain T Zaveri; Roberto Ciccocioppo
Journal:  Addict Biol       Date:  2017-06-21       Impact factor: 4.280

5.  Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A.

Authors:  Talakad G Lohith; Sami S Zoghbi; Cheryl L Morse; Maria F Araneta; Vanessa N Barth; Nancy A Goebl; Johannes T Tauscher; Victor W Pike; Robert B Innis; Masahiro Fujita
Journal:  J Nucl Med       Date:  2012-02-06       Impact factor: 10.057

6.  Regarding "Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system".

Authors:  David A Gorelick
Journal:  Biol Psychiatry       Date:  2007-05-25       Impact factor: 13.382

7.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

Review 8.  Influence of stress associated with chronic alcohol exposure on drinking.

Authors:  Howard C Becker
Journal:  Neuropharmacology       Date:  2017-04-19       Impact factor: 5.250

9.  Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Authors:  Lawrence Toll; Taline V Khroyan; Willma E Polgar; Faming Jiang; Cris Olsen; Nurulain T Zaveri
Journal:  J Pharmacol Exp Ther       Date:  2009-09-22       Impact factor: 4.030

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.